ConductScience.org, home

Paper30167331

CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion.

Preusser M and 7 others. ESMO Open, 2018. Cited by 36 papers, by iCite.

Cite this record

ConductScience Library. CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion. Papers, record 30167331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30167331

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion.
PubMed
Journal
ESMO Open
PubMed
Year
2018
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
36
iCite
Relative citation ratio, by iCite
1.06
iCite
Revised in PubMed
2021-02-08
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Preusser MMatthias
2De Mattos-Arruda LLeticia
3Thill MMarc
4Criscitiello CCarmen
5Bartsch RRupert
6Ruhstaller TThomas
7de Azambuja EEvandro
8Zielinski CCChristoph C

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Erratum in30962965Correction: CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion.https://conductscience.org/library/papers/30962965

Source PubMed

Download CSV of comments and corrections

References54

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
126560360Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.Sci Transl Med2015https://conductscience.org/library/papers/26560360PubMed
227406875Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies.Endocr Relat Cancer2016https://conductscience.org/library/papers/27406875PubMed
324011769Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer.Breast2013https://conductscience.org/library/papers/24011769PubMed
425633797The history and future of targeting cyclin-dependent kinases in cancer therapy.Nat Rev Drug Discov2015https://conductscience.org/library/papers/25633797PubMed
5283279983rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).Ann Oncol2017https://conductscience.org/library/papers/28327998PubMed
68137296Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining.Cancer Res1994https://conductscience.org/library/papers/8137296PubMed
722149876Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.N Engl J Med2012https://conductscience.org/library/papers/22149876PubMed
820125090Management of breast cancer with targeted agents: importance of heterogeneity. [corrected].Nat Rev Clin Oncol2010https://conductscience.org/library/papers/20125090PubMed
926977878Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.Cancer Cell2016https://conductscience.org/library/papers/26977878PubMed
1022114931Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.Breast Cancer Res2011https://conductscience.org/library/papers/22114931PubMed
11326386Current status of estrogen and progesterone receptors in breast cancer.Cancer1977https://conductscience.org/library/papers/326386PubMed
1228968163MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.J Clin Oncol2017https://conductscience.org/library/papers/28968163PubMed
1324807915Discordance in hormone receptor status among primary, metastatic, and second primary breast cancers: biological difference or misclassification?Oncologist2014https://conductscience.org/library/papers/24807915PubMed
1424185512ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.Nat Genet2013https://conductscience.org/library/papers/24185512PubMed
1525002028CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.Cancer Cell2014https://conductscience.org/library/papers/25002028PubMed
1616291983Distinct sets of genetic alterations in melanoma.N Engl J Med2005https://conductscience.org/library/papers/16291983PubMed
1710473088Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer.Clin Cancer Res1999https://conductscience.org/library/papers/10473088PubMed
1827717303Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.N Engl J Med2016https://conductscience.org/library/papers/27717303PubMed
1927801670Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor.Oncotarget2016https://conductscience.org/library/papers/27801670PubMed
2018316794
Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.
J Clin Oncol2008https://conductscience.org/library/papers/18316794PubMed

See all 54 referencesDownload CSV of references

Cited by27

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 36 citations.

PMIDTitleJournalYearIn PapersSource
42573210miR-640 Enhances Abemaciclib Sensitivity by Suppressing CDK Inhibitor Resistance-Associated Genes in Breast Cancer Cells.J Cell Mol Med2026https://conductscience.org/library/papers/42573210PubMed
42073594Real-World Outcomes of Palbociclib with Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer: A Retrospective Study from Saudi Arabia.Cancers (Basel)2026https://conductscience.org/library/papers/42073594PubMed
40110795Insulin-like growth factor 2 as a driving force for exponential expansion and differentiation of the neonatal thymus.Development2025https://conductscience.org/library/papers/40110795PubMed
39810652Real-world study of patients with HR+/ HER2- metastatic breast cancer treated with palbociclib and fulvestrant.Future Oncol2025https://conductscience.org/library/papers/39810652PubMed
39330025Therapeutic Prospects of Abemaciclib for Patients with Endometrial Cancer.Curr Oncol2024https://conductscience.org/library/papers/39330025PubMed
37889120Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer.Clin Cancer Res2024https://conductscience.org/library/papers/37889120PubMed
37567880Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer.NPJ Breast Cancer2023https://conductscience.org/library/papers/37567880PubMed
37384539Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers.Cancer Res2023https://conductscience.org/library/papers/37384539PubMed
36792625Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in ER-positive breast cancer models.Sci Rep2023https://conductscience.org/library/papers/36792625PubMed
36153348Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer.NPJ Precis Oncol2022https://conductscience.org/library/papers/36153348PubMed
35582612Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem.Cancer Drug Resist2020https://conductscience.org/library/papers/35582612PubMed
35133007
Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study.
Int J Cancer2022https://conductscience.org/library/papers/35133007PubMed
34999182Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response.Pharmacol Ther2022https://conductscience.org/library/papers/34999182PubMed
34944934Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer.Cancers (Basel)2021https://conductscience.org/library/papers/34944934PubMed
33452764Exploring the five different genes associated with PKCα in bladder cancer based on gene expression microarray.J Cell Mol Med2021https://conductscience.org/library/papers/33452764PubMed
33353132
Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2- Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series.
J Pers Med2020https://conductscience.org/library/papers/33353132PubMed
33332933Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL).Cancer Res Treat2021https://conductscience.org/library/papers/33332933PubMed
32907621Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns.Genome Med2020https://conductscience.org/library/papers/32907621PubMed
32833070Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?Arch Gynecol Obstet2020https://conductscience.org/library/papers/32833070PubMed
32691623Inhibition of CDK2/CyclinE1 by xanthones from the mangosteen (Garcinia mangostana): a structure-activity relationship study.Nat Prod Res2021https://conductscience.org/library/papers/32691623PubMed

See all 27 cited byDownload CSV of cited by

Genes29

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ABCB15243PubTator's text mininghttps://conductscience.org/library/genes/5243NCBI Gene
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
AKT2208PubTator's text mininghttps://conductscience.org/library/genes/208NCBI Gene
CCND1595PubTator's text mininghttps://conductscience.org/library/genes/595NCBI Gene
CCNE1898PubTator's text mininghttps://conductscience.org/library/genes/898NCBI Gene
CDK41019PubTator's text mininghttps://conductscience.org/library/genes/1019NCBI Gene
CDK61021PubTator's text mininghttps://conductscience.org/library/genes/1021NCBI Gene
CDKN2A1029PubTator's text mininghttps://conductscience.org/library/genes/1029NCBI Gene
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
ERBB32065PubTator's text mininghttps://conductscience.org/library/genes/2065NCBI Gene
EREG2069PubTator's text mininghttps://conductscience.org/library/genes/2069NCBI Gene
ESR12099PubTator's text mininghttps://conductscience.org/library/genes/2099NCBI Gene
FGFR12260PubTator's text mininghttps://conductscience.org/library/genes/2260NCBI Gene
IGF1R3480PubTator's text mininghttps://conductscience.org/library/genes/3480NCBI Gene
INPP4B8821PubTator's text mininghttps://conductscience.org/library/genes/8821NCBI Gene
MAP2K75609PubTator's text mininghttps://conductscience.org/library/genes/5609NCBI Gene
MAPK15594PubTator's text mininghttps://conductscience.org/library/genes/5594NCBI Gene
MTOR2475PubTator's text mininghttps://conductscience.org/library/genes/2475NCBI Gene
NR4A13164PubTator's text mininghttps://conductscience.org/library/genes/3164NCBI Gene

See all 29 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/30167331

GET https://conductscience.org/api/papers/v1/30167331/references?page=2